Evolocumab leads to acute attack of primary angle-closure glaucoma:a case report
10.3969/j.issn.1006-6187.2025.10.011
- VernacularTitle:依洛尤单抗导致闭角型青光眼急性发作一例报道
- Author:
Man WU
1
;
Yingying LUO
;
Linong JI
Author Information
1. 100044 北京大学人民医院内分泌科;厦门市第三医院内分泌科
- Publication Type:Journal Article
- Keywords:
Proprotein convertase subtilisin type 9 inhibitor;
Glaucoma;
Intraocular pressure;
Blood lipids
- From:
Chinese Journal of Diabetes
2025;33(10):789-792
- CountryChina
- Language:Chinese
-
Abstract:
Evolocumab is a lipid-lowering agent used to reduce low-density lipoprotein cholesterol levels and decrease the all-cause mortality rate of cardiovascular diseases.There are few ocular adverse reactions when the drug is used clinically.This article reports a case of primary angle-closure glaucoma.After three sessions of lipid-lowering treatment with the proprotein convertase subtilisin type 9(PCSK9)inhibitor Evolocumab,the patient developed swelling and pain in the left eye and blurred vision.Ophthalmic examination revealed a significant increase in intraocular pressure in the left eye,suggesting an acute attack of angle-closure glaucoma.After treatment,the intraocular pressure dropped to the normal level.This article discusses this case and reviews relevant literature,suggesting that when using PCSK9 inhibitors in clinical practice,the ocular conditions of patients should be closely monitored,especially for those with risk factors for glaucoma.
